964 related articles for article (PubMed ID: 9610754)
1. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women.
Karasik D; Rosen CJ; Hannan MT; Broe KE; Dawson-Hughes B; Gagnon DR; Wilson PW; Visser M; Langlois JA; Mohan S; Kiel DP
Calcif Tissue Int; 2002 Oct; 71(4):323-8. PubMed ID: 12202958
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men.
Johansson AG; Forslund A; Hambraeus L; Blum WF; Ljunghall S
J Bone Miner Res; 1994 Jun; 9(6):915-21. PubMed ID: 7521562
[TBL] [Abstract][Full Text] [Related]
5. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
6. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
7. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment.
Ferrante E; Giavoli C; Porretti S; Vassallo E; Ronchi CL; Lania AG; Beck-Peccoz P; Spada A
Horm Metab Res; 2006 May; 38(5):352-5. PubMed ID: 16718634
[TBL] [Abstract][Full Text] [Related]
9. Amino acid profiles in adults with growth hormone (GH) deficiency before and during GH replacement therapy.
Fernholm R; Thoren M; Hoybye C; Anderstam B; Pernow Y; Saaf M; Hall K
Growth Horm IGF Res; 2009 Jun; 19(3):206-11. PubMed ID: 18990596
[TBL] [Abstract][Full Text] [Related]
10. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
11. A potentially deleterious role of IGFBP-2 on bone density in aging men and women.
Amin S; Riggs BL; Atkinson EJ; Oberg AL; Melton LJ; Khosla S
J Bone Miner Res; 2004 Jul; 19(7):1075-83. PubMed ID: 15176989
[TBL] [Abstract][Full Text] [Related]
12. Increased serum concentration of IGFBP-4 and IGFBP-5 in healthy adults during one month's treatment with supraphysiological doses of growth hormone.
Ehrnborg C; Ohlsson C; Mohan S; Bengtsson BA; Rosén T
Growth Horm IGF Res; 2007 Jun; 17(3):234-41. PubMed ID: 17347011
[TBL] [Abstract][Full Text] [Related]
13. The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD.
Lange M; Müller J; Svendsen OL; Kastrup KW; Juul A; Feldt-Rasmussen U
Clin Endocrinol (Oxf); 2005 Jan; 62(1):18-23. PubMed ID: 15638865
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
15. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
16. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures].
Kuzma M; Payer J
Cas Lek Cesk; 2010; 149(5):211-6. PubMed ID: 20629339
[TBL] [Abstract][Full Text] [Related]
17. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
